Summary
- iSpecimen has filed to raise $20 million in an IPO.
- The firm operates a human biospecimen online marketplace.
- ISPN has grown from a small revenue base and operates in a promising industry, so I look forward to learning about the IPO's pricing and valuation assumptions.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
iSpecimen (ISPN) has filed to raise $20 million in an IPO of its common stock, according to an S-1 registration statement.
The firm offers an online marketplace for the purchase of biospecimens for research.
ISPN is operating in a growth industry but is still a small company.
When we learn more about the IPO, I’ll provide an update.
Company & Technology
Lexington, Massachusetts-based iSpecimen was founded to create a marketplace connecting biopharmaceutical and academic researchers with a large selection of human biospecimens and related information.
Management is headed by founder, president and CEO Christopher Ianelli, who was previously founder and CEO of Abkine Pharmaceuticals and Managing Director at Leerink Partners, an investment bank.
Below is a brief overview video of the iSpecimen Marketplace:
